In the EPIC-CAD trial, edoxaban monotherapy was associated with better net clinical benefit than edoxaban plus a single antiplatelet agent, when given as long-term antithrombotic therapy, in patients ...

Despite consistent recommendations from clinical guidelines, data from randomized trials on a long-term antithrombotic treatment strategy for patients with atrial fibrillation and stable coronary ...

The rate of net adverse clinical events (NACE) at 1 year was 6.8% among patients treated with edoxaban (Savaysa; Daiichi Sankyo) alone and 16.2% among those treated with edoxaban plus antiplatelet ...

Antiplatelets are particularly beneficial for people who have had a previous heart attack or stroke, those with CAD, or ...

The announcement follows the presentation of data from sub-analyses of the SANTORINI observational study and ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular ...

Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) today and set a price target ...

In both trials, patients were randomized either to anticoagulation (edoxaban in NOAH—AFNET 6 and apixaban in ARTESiA) or no anticoagulation in order to compare efficacy and safety outcomes in ...

One type of reversal agent (examples include andexanet-α for edoxaban, rivaroxaban, or apixaban and idarucizumab for dabigatran) can help with specific DOACs, while a more general reversal agent ...